Monte Rosa director granted 25,800 stock options

Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock.

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. Following this grant, he holds options for 25,800 shares. The options vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as he continues serving the company.

Insider Trade Summary

Grant/Award: 25,800 shares

Grant/Award 1 txn

Insider Skvarka Jan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,800	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 25,800 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

Key Figures

Stock options granted: 25,800 options Exercise price: $17.10 per share Expiration date: June 11, 2036 +3 more

6 metrics

Stock options granted 25,800 options Grant to director Jan Skvarka on June 11, 2026

Exercise price $17.10 per share Exercise price for granted stock options

Expiration date June 11, 2036 Option term end date

Underlying shares 25,800 shares Common stock underlying granted options

Post-grant option holdings 25,800 options Total options held following this transaction

Vesting date trigger June 11, 2027 Latest vesting date, or earlier at next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-11T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Monte Rosa Therapeutics (GLUE) disclose in this Form 4 filing?

Monte Rosa Therapeutics reported that director Jan Skvarka received a grant of 25,800 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as equity-based compensation rather than an open-market stock purchase or sale.

How many stock options did Jan Skvarka receive from Monte Rosa Therapeutics (GLUE)?

Jan Skvarka received 25,800 stock options linked to Monte Rosa Therapeutics common stock. Each option represents the right to buy one share, so the grant covers 25,800 underlying shares once the options vest and are exercised, subject to the plan’s terms.

What is the exercise price and expiration date of the GLUE options granted to Jan Skvarka?

The granted options have an exercise price of $17.10 per share and expire on June 11, 2036. This means Skvarka can choose to buy shares at $17.10 any time after vesting and before the June 11, 2036 expiration date, if he remains eligible.

When do Jan Skvarka’s Monte Rosa Therapeutics (GLUE) options vest?

The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders. Vesting is conditioned on his continued service with Monte Rosa Therapeutics through that vesting date or meeting.

Does this GLUE Form 4 show director Jan Skvarka buying or selling shares on the market?

No, the Form 4 shows a grant of stock options as compensation, not an open-market trade. The transaction is coded as an award, giving Skvarka the right to buy shares later, rather than reflecting an immediate stock purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Skvarka Jan

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.1	06/11/2026		A		25,800		(1)	06/11/2036	Common Stock	25,800	$0	25,800	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Markus Warmuth, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)